Share on StockTwits

Epizyme (NASDAQ:EPZM) CEO Robert J. Gould unloaded 30,000 shares of the stock in a transaction that occurred on Tuesday, July 1st. The shares were sold at an average price of $31.53, for a total transaction of $945,900.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Shares of Epizyme (NASDAQ:EPZM) traded up 4.36% on Thursday, hitting $34.24. 227,798 shares of the company’s stock traded hands. Epizyme has a 52-week low of $18.10 and a 52-week high of $45.72. The stock’s 50-day moving average is $26.0 and its 200-day moving average is $26.53. The company’s market cap is $1.126 billion.

Epizyme (NASDAQ:EPZM) last released its earnings data on Tuesday, May 13th. The company reported ($0.22) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.47) by $0.25. Analysts expect that Epizyme will post $-1.78 EPS for the current fiscal year.

Epizyme, Inc is a clinical stage biopharmaceutical company that discovers, develops and plans to commercialize personalized therapeutics for patients with genetically defined cancers.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.